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a b s t r a c t
Introduction: Rotavirus disease in Mongolia is estimated to cause more than 50 deaths yearly and many
more cases and hospitalizations. Mongolia must self-finance new vaccines and does not automatically
access Gavi prices for vaccines. Given the country’s limited resources for health, it is critical to assess
potential new vaccine programs. This evaluation estimates the impact, cost-effectiveness, and budget
implications associated with a nationwide rotavirus vaccine introduction targeting infants as part of
the national immunization program in Mongolia, in order to inform decision-making around introduc-
tion.
Methods: The analysis examines the use of the two-dose vaccine ROTARIX, and three-dose vaccines
ROTAVAC and RotaTeq compared to no vaccination from the government and the societal perspective.
We use a modelling approach informed by local data and published literature to analyze the impact and
cost-effectiveness of rotavirus vaccination over a ten-year time period starting in 2019, using a 3% dis-
count rate. Our main outcome measure is the incremental cost-effectiveness ratio (ICER) expressed as
US dollar per DALY averted. We assessed uncertainty around a series of parameters through univariate
sensitivity analysis.
Results: Rotavirus vaccination in Mongolia could avert more than 95,000 rotavirus cases and 271 deaths,
over 10 years. Averted visits and hospitalizations represent US$2.4 million in health care costs saved by
the government. The vaccination program cost ranges from $6 to $11 million depending on vaccine
choice. From the governmental perspective, ICER ranged from $412 to $1050 and from $77 to $715 when
considering the societal perspective. Sensitivity analysis highlights vaccine price as the main driver of
uncertainty.
Conclusion: Introduction of rotavirus vaccination is likely to be highly cost-effective in Mongolia, with
ICERs estimated at only a fraction of Mongolia’s per capita GDP. From an economic standpoint,
ROTAVAC is the least costly and most cost-effective product choice.
 2019 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).
1. Introduction
Child mortality has been declining worldwide as a result of
socioeconomic development and child survival interventions.
However, diarrhea remains a primary cause of mortality, and rota-
virus is responsible for a large share of these deaths. In 2013, rota-
virus was responsible for 215,000 of the 578,000 childhood
diarrheal deaths worldwide with more than 90% of these deaths
occurring in low- and middle-income countries [1]. In Mongolia,
the World Health Organization (WHO) and the Centers for Disease
Control and Prevention estimated that over 50 children under five
years of age die of rotavirus infection annually. Diarrhea is also a
https://doi.org/10.1016/j.vaccine.2018.12.056
0264-410X/ 2019 The Authors. Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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leading cause of childhood morbidity in Mongolia [2–6]. A 2013
social indicator sample survey reported a prevalence of diarrhea
of 8.2% in children under five years, with higher prevalence in rural
areas. The highest period-prevalence is seen among children 12–
23 months [7].
Since 2009, WHO has recommended rotavirus vaccines to be
included in national immunization programs as part of a compre-
hensive strategy to control childhood diarrheal diseases [8]. Two
rotavirus vaccines have been licensed and used globally: the
monovalent vaccine ROTARIX (GlaxoSmithKline Biologicals, Rix-
ensart, Belgium) and the pentavalent vaccine RotaTeq (Merck &
Co, Inc., West Point, PA, USA). Clinical trials and post-
introduction evaluations have indicated vaccine efficacy and/or
effectiveness ranges from approximately 70% to 100% in high-
and upper-middle-income countries to approximately 50% to 70%
in lower-income countries in Africa and Asia [9,10]. ROTAVAC
(Bharat Biotech International Limited, India), another monovalent
vaccine, received WHO prequalification for use globally in early
2018 and has been licensed and used in India since 2017 [11]. Data
from a clinical trial in India, a lower-middle-income setting where
efficacy is expected to be lower, showed 56% efficacy of ROTAVAC
[12].
One of the objectives of Mongolia’s National Program on Infec-
tious Diseases Prevention and Control is to use surveillance-based
evidence to inform decision-making around new vaccine introduc-
tion. Since 2009, Mongolia has participated in the WHO Western
Pacific Regional Office rotavirus surveillance network to collect
data on the rotavirus-positive proportion of diarrhea cases admit-
ted to hospitals. In addition, Mongolia’s comprehensive multi-year
plan recommends that rotavirus vaccines be considered for the
routine childhood immunization schedule in the near future [13].
Mongolia recently transitioned from Gavi support and has to fully
self-finance any new vaccines. As a transitioned country, Mongolia
cannot automatically access Gavi-negotiated prices for ROTARIX,
the most common product choice among Gavi countries. In this sit-
uation, impact, cost-effectiveness, affordability, and budget impact
are among the key factors to inform decisions around introducing
rotavirus vaccination and which product to choose. The purpose of
this evaluation is to estimate the potential impact, cost-
effectiveness, and budget implications associated with infant rota-
virus vaccination as part of the national immunization program in
Mongolia compared to no vaccination, assessing the three different
rotavirus products available at the time of writing, and to provide
data needed to prepare for potential introduction.
2. Materials and methods
The immunization program in Mongolia has been very success-
ful at maintaining very high coverage for traditional antigens.
While the Ministry of Health is responsible for policy making and
setting health regulations, immunization services are part of the
health services provided by local governments and city corpora-
tions in district health facilities and family health centers [13].
This analysis examines infant vaccination with ROTARIX
administered at 2 and 4 months along with Diphtheria, Tetanus,
and Pertussis (DTP) at DTP dose 1 (DTP1) and DTP dose 2 (DTP2).
We also examine ROTAVAC and RotaTeq vaccines administered
to the same group, following the same schedule, with a third dose
at 6 months along with DTP dose 3 (DTP3). We compare the impact
and cost-effectiveness of rotavirus vaccination to no vaccination,
over a ten-year time period starting in 2019. Our analysis viewed
2019 as a potential timeline for starting a rotavirus vaccination
program if it became a priority based on other ongoing immuniza-
tion activities and looks at ten years to inform medium term plan-
ning and budgeting.
When infected with rotavirus, children may or may not get
rotavirus gastroenteritis (RVGE). Children with RVGE will experi-
ence a non-severe or severe episode. Non-severe episodes result
in recovery with or without outpatient care. Severe episodes result
in recovery or death with or without outpatient and/or inpatient
care (Fig. 1). This analysis tracks costs and benefits of rotavirus dis-
ease and rotavirus vaccination of infants over 10 consecutive birth
cohorts following each cohort until they reach age 5. We exclude
any indirect benefits of vaccination, assuming herd effect would
have minimal impact considering the high vaccine coverage in
Mongolia. Costs and benefits are discounted using a 3% annual rate
Fig. 1. Model schematic.
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[14]. Results are presented from the government and the societal
perspective. All monetary units were adjusted to 2017 US$ using
currency exchange rate from the Central Bank of Mongolia (US$
1 = MNT 2438) and the U.S. Consumer Price Index (CPI) from the
United States Department of Labor, Bureau of Labor Statistics.
We calculate the incremental cost-effectiveness ratio (ICER) by
dividing the difference between incremental vaccine program
costs and averted health care costs by the number of disability-
adjusted life-years (DALY) averted by the intervention. We elected
to use the discounted cost per averted DALY as our main outcome
measure. DALYs are commonly use in cost-effectiveness analysis,
partly because of their comparability across settings and interven-
tions. Additional outcomes measured include the number of
deaths, hospitalizations, outpatient visits, and cases averted; the
incremental cost of the vaccination program; and health care costs
averted. This analysis examines budget implications, providing
undiscounted annual costs of the vaccination program over the
ten-year time horizon of the analysis.
2.1. Model
We used UNIVAC (version 1.3.07), a universal static impact and
cost-effectiveness decision support model used in many studies
worldwide [15–18]. Developed for use in low- and middle-
income countries, UNIVAC provides estimates of the potential
impact and cost-effectiveness of rotavirus and other vaccines. UNI-
VAC follows methods developed for the TRIVAC model, which have
been described elsewhere [18]. Model inputs include burden of
disease, vaccine schedule, efficacy, coverage, timeliness of vaccina-
tion, vaccine program costs, and health care costs. Input parame-
ters were collected from the literature and local sources to reflect
country context. All data inputs and assumptions were discussed
and validated by a group of experts that participated in this cost-
effectiveness analysis. The group of experts included members
from the Expanded Programme on Immunization and the National
Center for Communicable Diseases; staff from the Sukhbaatar dis-
trict surveillance hospital; the surveillance department of the
National Maternal and Child Disease Center; the National Center
for Health Development; and the WHO.
2.2. Disease burden
We estimated severe and non-severe RVGE cases, outpatient
visits, and hospitalizations in Mongolia using data from different
sources. In the absence of RVGE incidence data, we based our esti-
mates on health facility data and then adjusted for treatment seek-
ing to estimate RVGE incidence. We first calculated rates of
outpatient visits and hospitalizations using the number of diarrhea
cases in children under five years (outpatient and inpatient)
reported by the Center for Health Development and population
data from the National Statistical Office [19,20]. We assumed all
hospitalizations were for severe diarrhea and applied the
rotavirus-attributable fraction observed among diarrhea admis-
sions in two hospitals of Ulaanbaatar city reported by the surveil-
lance network in 2015 [21]. As rotavirus positivity is usually lower
in outpatient settings, we applied half the rotavirus-attributable
fraction to determine non-severe RVGE relative to all diarrhea
[22]. After obtaining estimates of health facility utilization, we
then calculated incidence of RVGE as 4729 per 100,000 children
under five years, using a treatment seeking rate of 46.8% for outpa-
tient visits [7] and a rate of 80% for hospitalizations, assuming that
a larger proportion of severe cases seek treatment in an inpatient
setting. Local information suggests that children often visit an out-
patient setting before being hospitalized, resulting in facility uti-
lization that exceeds the number of severe cases. To account for
uncertainty, we examined other potential incidence rates. As a
high input, we used 10,000 per 100,000 cases in children under five
years as demonstrated by Bilcke et al. in a global systematic review
and meta-analysis [23], which is consistent with the incidence
level observed by Zaman et al. in the placebo arm of the RotaTeq
randomized controlled trial in Bangladesh and Vietnam [24]. As a
low input, we used our base case assumptions accounting for rota-
virus positivity observed in other countries of the region [25,26].
We used a disease mortality rate of 18 per 100,000 (16.5–20) per
year in children under five years as reported by Tate et al. [1]. Dis-
ease event age distribution is based on surveillance data [21]. DALY
weights for moderate and severe diarrhea in 2013 were 0.188 and
0.247, respectively [27]. We assumed the average duration of
rotavirus disease to be 3 days for non-severe cases and 7 days for
Table 1
Input parameters for estimating disease burden.
Parameter Estimate Scenarios Source/s
Low High
Annual incidence per 100,000 < 5 years
Rotavirus (non-severe) cases 3060 – – Assumption derived from [7,19–21]
Rotavirus (non-severe) outpatient visits 1432 – – Assumption derived from [7,19–21]
Rotavirus (severe) cases 1670 – – Assumption derived from [7,19–21]
Rotavirus (severe) outpatient visits 781 – – Assumption derived from [7,19–21]
Rotavirus (severe) hospitalizations 1336 795 2825 Assumption derived from [7,19–21]
Rotavirus deaths 18 16.5 20 [1]
Disability weight for DALY calculations
Rotavirus (non-severe) cases 18.8% – – [27]
Rotavirus (severe) cases 24.7% – – [27]
Mean duration of illness (in days)
Rotavirus (non-severe) cases 3 – – [28]
Rotavirus (severe) cases 7 – – [28]
Cumulative age distribution of disease, cases, and deaths
<1 m: 4% – – Assumption
<2 m: 7% – – Assumption
<3 m 11% – – Assumption
<6 m: 22% – – [21]
<12 m: 70% – – [21]
<24 m: 97% – – [21]
<36 m: 98% – – Assumption
<48 m: 99% – – Assumption
<59 m: 100% – – [21]
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severe cases [28]. All data inputs used to characterize disease bur-
den are displayed in Table 1.
2.3. Vaccine coverage and efficacy
As rotavirus vaccine is anticipated to be delivered alongside DTP
according to WHO recommendations, we use DTP coverage as
reported by WHO and UNICEF, assuming constant coverage across
the study period [29]. Coverage for DTP2 was assumed to be half-
way between DTP1 and DTP3. We assumed that timeliness of rota-
virus vaccination would be similar to that for DTP reported in the
2013 Mongolia Multiple Indicator Cluster Survey (MICS) study
[30]. Efficacy and waning inputs are based on work from Clark
et al., who estimated efficacy of rotavirus vaccination by time since
administration of the last dose, extracting data from all random-
ized controlled trials in very low-, low-, and high-mortality set-
tings [31]. Mongolia data inputs correspond to low child
mortality and 81% (62%  87%) efficacy two weeks after receiving
the last dose. We further assumed that one dose of vaccine would
confer half the efficacy of the last dose. In the absence of data to
support different efficacy for different rotavirus vaccines, we
assume similar efficacy and waning level for ROTARIX, RotaTeq
and ROTAVAC, as done in similar analyses [32]. Per model input
requirements, the same efficacy value is applied to all endpoints.
Input parameters for vaccine coverage, timeliness, and vaccine
impact are available from Table 2.
2.4. Vaccine price and delivery cost
Mongolia transitioned out of support from Gavi, the Vaccine
Alliance in 2016 and now fully self-finances new vaccines [33].
Although Gavi-secured pricing agreements with manufacturers
allow fully self-financing countries to benefit from Gavi-like prices
for some vaccines [34], it does not automatically apply to Mongolia
for use of ROTARIX as the country did not adopt while still eligible
for support. To introduce ROTARIX, the Mongolian government
will have to enter into negotiations with the manufacturer
[35,36]. As the potential outcome of this negotiation is uncertain,
we used price data reported by other middle-income countries that
do not access Gavi prices [37]. The average 2016 price was $6.20
per dose [38]. We utilized prices of $1.00 and $3.50 per dose for
ROTAVAC and RotaTeq, respectively [34,39].
In addition to vaccine price, we included procurement of safe
disposal bags at a unit price of $0.80. We assume a standard
wastage rate of 5% for ROTARIX and RotaTeq and 25% for ROTA-
VAC, based on the number of doses per container. While
ROTARIX and RotaTeq have a single dose presentation, ROTA-
VAC is available in 10- or 5-dose vial, potentially generating
higher wastage [11,40]. We assume international handling and
delivery of vaccines will represent 3.5% and 8% of vaccine price
respectively [41,42].
To our knowledge, no costing study has been carried out in
Mongolia to inform the incremental health system cost of deliver-
Table 2
Input parameters for estimating rotavirus vaccine (RV) coverage, timeliness and health impact.
Parameter Estimate Scenarios Source/s
Low High
Rotavirus vaccine (RV) coverage and timeliness parameters
Total coverage in year 2019
DTP1 99% 70% 100% [29]
DTP2 99% 70% 100% [29]
DTP3 99% 70% 100% [29]
Percent of total coverage of DTP1 achieved by age in year 2019 (proxy for RV doses given with DTP1)
6 m 94% 70% 100% [7,30]
12 m 95% 70% 100%
24 m 95% 70% 100%
Percent of total coverage of DTP2 achieved by age in year 2019 (proxy for RV doses given with DTP2)
6 m 91% 64% 92% [7,30]
12 m 92% 70% 100%
24 m 92% 70% 100%
Percent of total coverage of DTP3 achieved by age in year 2019 (proxy for RV doses given with DTP3)
6 m 86% 61% 87% [7,30]
12 m 89% 70% 100%
24 m 89% 70% 100%
Rotavirus vaccine (RV) health impact parameters
Vaccine efficacy 2 weeks after vaccination
1 dose 41% 31% 44% Assumption
2 doses 81% 62% 87% [31]
3 doses 81% 62% 87% [31]
Duration of vaccine efficacy, 1 dose
After 6 m 36% 28% 39% [31]
After 12 m 36% 27% 38% [31]
After 24 m 34% 26% 37% [31]
Duration of vaccine efficacy, 2 doses
After 6 m 72% 55% 78% [31]
After 12 m 71% 54% 76% [31]
After 24 m 68% 52% 73% [31]
Duration of vaccine efficacy, 3 doses
After 6 m 72% 55% 78% [31]
After 12 m 71% 54% 76% [31]
After 24 m 68% 52% 73% [31]
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ing rotavirus vaccine. We use data from a 2018 systematic review
on the cost of immunization programs, using incremental cost-per-
dose estimates reported by middle-income countries [43]. Data
inputs used to estimate the vaccine program cost are available
from Table 3.
2.5. Health service costs
Outpatient cost estimates were based on WHO-CHOICE service
delivery unit cost estimates for Mongolia as well as commodity
costs. We assumed government cost encompasses direct medical
cost, while households cost includes direct non-medical costs.
We did not include indirect costs, a conservative assumption due
to lack of data. Cost per outpatient visit is the sum of the WHO-
CHOICE cost in a primary facility setting and 6 oral rehydration
salts (ORS) packets per day for 3 days, valuing ORS solution at
$0.29 per packet, per MSH’s International Medical Products Price
Guide [44]. Based on a 2017 PATH literature review examining
all diarrhea cost-of-illness studies reporting data for low- and
middle-income countries, we calculated that direct medical costs
accounted for 70% of all direct costs. We applied this percentage
to calculate direct non-medical costs. We estimated the govern-
ment cost of an outpatient visit at $7.29 and households cost at
$2.64 (Table 3).
Inpatient costs were estimated using a mix of local data avail-
able from an unpublished cost of rotavirus diarrhea study and
modelled data based on 2010 WHO-CHOICE data. The study esti-
mated household costs linked to an episode of diarrhea, accounting
for households’ preparation and transportation costs, and out-of-
pocket payments prior to and during hospitalization. The study
also collected information from medical records to assess hospital
direct costs. This information was combined with WHO-CHOICE
data on bed day costs at a secondary level hospital for Mongolia
and a four-day length of stay. We estimated the government cost
of an inpatient stay at $77.93 and the households cost at $96.27
(Table 3).
2.6. Scenario analysis and sensitivity analysis
We examined scenarios assessing the use of other available
rotavirus vaccines RotaTeq and ROTAVAC and also used univari-
ate sensitivity analysis to highlight the main drivers of cost-
effectiveness of rotavirus vaccination in Mongolia. Parameters
explored in the sensitivity analysis include incidence of severe
RVGE hospitalizations, incidence of RVGE deaths, vaccine efficacy,
vaccine coverage, vaccine price per dose, incremental health sys-
Table 3
Input parameters for estimating health service costs and rotavirus vaccine program costs (2017 US$).
Parameter Estimate Scenarios Source/s
Low High
Rotavirus program costs
International handling (% of vaccine price) 3.5% – – Assumption
International delivery (% of vaccine price) 8% – – Assumption
Incremental system cost per dose $1.91 $0.50 $2.50 [43], assumption for Low and High
ROTARIX vaccine price per dose $6.20 $2.02 $15.76 [38]
ROTARIX wastage 5% – – Assumption
RotaTeq vaccine price per dose $3.50 $3.20 $7 [11], assumption for Low and High
RotaTeq wastage 5% – – Assumption
ROTAVAC price per dose $1 $0.5 $2 [11], assumption for Low and High
ROTAVAC wastage 25% – – Assumption
Health service costs
Government cost per outpatient visit $7.29 $3.65 $14.58 Modelled using WHO-CHOICE, assumption for Low and High
Household cost per outpatient visit $2.64 $1.32 $5.28
Government cost per inpatient admission $77.93 $38.97 $155.86
Household cost per inpatient admission $96.27 $48.13 $192.54
Table 4
Health and economics benefits (10 cohorts vaccinated over the period 2019–2028,
costs discounted, 2017 US$).
ROTARIX
No vaccine With vaccine Averted
Total non-severe cases <5 yrs 93,624 31,530 62,095
Total severe cases <5 yrs 51,096 17,207 33,888
Total outpatient visits 67,709 22,802 44,907
Total hospitalizations 40,877 13,766 27,111
Total deaths <5 yrs 409 138 271
DALYs 10,701 3607 7094
Total government health service costs
Total outpatient visit costs $430,306 $145,031 $285,275
Total hospitalization costs $2,777,024 $935,974 $1,841,050
Total societal health service costs
Total outpatient visit costs $586,137 $197,553 $388,584
Total hospitalization costs $6,207,592 $2,092,220 $4,115,372
Total vaccination program costs – $9,574,121 –
RotaTeq
No vaccine With vaccine Averted
Total non-severe cases <5 yrs 93,624 28,815 64,809
Total severe cases <5 yrs 51,096 15,726 35,370
Total outpatient visits 67,709 20,839 46,870
Total hospitalizations 40,877 12,581 28,296
Total deaths <5 yrs 409 126 283
DALYs 10,701 3293 7408
Total government health service costs
Total outpatient visit costs $430,306 $132,435 $297,871
Total hospitalization costs 2,777,024 854,684 1,922,341
Total societal health service costs
Total outpatient visit costs 586,137 180,395 405,742
Total hospitalization costs 6,207,592 1,910,508 4,297,084
Total vaccination program costs – $9,407,658 –
ROTAVAC
No vaccine With vaccine Averted
Total non-severe cases <5 yrs 93,624 28,815 64,809
Total severe cases <5 yrs 51,096 15,726 35,370
Total outpatient visits 67,709 20,839 46,870
Total hospitalizations 40,877 12,581 28,296
Total deaths <5 yrs 409 126 283
DALYs 10,701 3293 7408
Total government health service costs
Total outpatient visit costs $430,306 $132,435 $297,871
Total hospitalization costs 2,777,024 854,684 1,922,341
Total societal health service costs
Total outpatient visit costs 586,137 180,395 405,742
Total hospitalization costs 6,207,592 1,910,508 4,297,084
Total vaccination program costs – $5,274,441 –
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tem cost per dose, inpatient admission costs, outpatient visit costs,
and discount rate. All parameters range values used for the sensi-
tivity analysis are available from Tables 1, 2 and 3.
3. Results
3.1. Base case scenario
Between 2019 and 2028, a rotavirus vaccination program in
Mongolia has the potential to prevent more than 62,000 non-
severe RVGE cases, approximately 34,000 severe cases, and 271
deaths. This corresponds to approximately 19,000 undiscounted
DALYs averted. We estimate that rotavirus vaccination would avert
44,900 outpatient visits and more than 27,000 hospitalizations,
representing $2.4 and $5 million in undiscounted health care costs
saved from the government and societal perspectives, respectively.
The use of ROTARIX would result in a cost-effectiveness ratio of
$1050 per DALY averted from the government perspective and
$715 from the societal perspective. Additional details on health
and economic benefits of rotavirus vaccination are available from
Table 4.
The cost of the vaccination program is projected to average $1.1
million per year, with the majority of the cost dedicated to vaccine
procurement (79%). This amount would be partially balanced by
savings made on health care costs averted, but with ROTARIX at
a price per dose of $6.20, the rotavirus vaccination program would
still represent a net cost of about $850,000 on average per year.
Fig. 2 shows the anticipated base case budget implications by year.
-300,000
-100,000
100,000
300,000
500,000
700,000
900,000
1,100,000
2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
US$
ROTARIX® vaccination program costs ROTARIX® averted healthcare costs
RotaTeq® vaccination program costs RotaTeq® averted healthcare costs
ROTAVAC® vaccination program costs ROTAVAC® averted healthcare costs
Fig. 2. Budget implications (Government perspective, all figures undiscounted).
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412
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0 200 400 600 800 1,000 1,200
ROTARIX®
RotaTeq®
ROTAVAC®
US$ per DALY 
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Fig. 3. Scenario analysis results: cost per DALY averted in US$ (costs and benefits discounted).
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3.2. Additional scenarios and one-way sensitivity analyses
We also explored the use of RotaTeq and ROTAVAC vaccines
instead of ROTARIX. Fig. 3 presents the cost per DALY averted for
each scenario and perspective. From the societal perspective, the
cost per DALY is $77 with ROTAVAC and $635 with RotaTeq.
From the government perspective, the cost per DALY averted is
$412 with ROTAVAC and $970 with RotaTeq.
The undiscounted results from the government perspective
(Table 5) indicate that budget impact varies greatly depending on
which vaccine is considered. While ROTARIX and RotaTeq repre-
sent a total vaccination program cost of almost $11 million, ROTA-
VAC results in a much lower cost of about $6 million. Accounting
for savings on health care costs averted from the government per-
spective, the net cost of the vaccination program with ROTAVAC
would be less than $3.5 million over 10 years.
Results of the one-way sensitivity analysis show that vaccine
price is a key driver of uncertainty of the results (Fig. 4). Other dri-
vers of uncertainty include the inpatient admission costs and the
rate of severe RVGE hospitalizations. These drivers were consistent
among products. Vaccine coverage has no impact on the ICER as it
affects costs and benefits equally.
4. Discussion
Our analysis shows that rotavirus vaccination in Mongolia has
the potential to avert a substantial disease burden and be highly
cost-effective. The cost per DALY averted by rotavirus vaccination
represents 28% and 19% of the GDP per capita ($3694 in 2016) from
the government and the societal perspectives, respectively [45].
WHO no longer recommend to compare the ICER to GDP per capita
and Mongolia has not yet defined a country specific threshold that
we could use. In an attempt to allow for comparability, we elected
to compare ICER to GDP per capita as done previously in the coun-
try [46]. While study results should be interpreted carefully, we
believe that they present conservative estimates as we only
explore the direct benefits of rotavirus vaccination. A prior cost-
effectiveness study found that pneumococcal conjugate vaccina-
tion at the Gavi price would be highly cost-effective in Mongolia,
similar to our findings for rotavirus vaccination [46]. In addition,
many similar studies in middle-income settings found rotavirus
vaccination to be a cost-effective intervention with ICERs ranging
from cost saving to cost-effective [47].
While the range of incremental cost-effectiveness ratio (ICER)
values shows that rotavirus vaccination is likely to be a highly
Table 5
Budget impact analysis (Government perspective, all figures in undiscounted US$).
ROTARIX ($6.30 per dose)
Fully vaccinated
children
Health system
cost
Vaccine
cost
Total vaccination
program
Averted Outpatient visits
cost
Averted Hospitalizations
cost
Net Cost
2019 59,725 228,305 871,493 1,099,798 34,645 223,584 841,569
2020 56,711 216,778 827,495 1,044,274 33,369 215,350 795,554
2021 56,072 214,344 818,204 1,032,548 33,323 215,052 784,174
2022 57,091 218,238 833,067 1,051,305 33,038 213,214 805,053
2023 59,070 225,799 861,928 1,087,727 32,862 212,078 842,787
2024 60,936 232,928 889,144 1,122,072 32,744 211,320 878,008
2025 61,895 236,592 903,130 1,139,722 32,627 210,564 896,530
2026 61,646 235,641 899,497 1,135,138 32,094 207,124 895,919
2027 60,575 231,545 883,863 1,115,408 31,603 203,952 879,854
2028 59,016 225,586 861,115 1,086,701 31,067 200,495 855,139
592,737 2,265,757 8,648,936 10,914,693 327,373 2,112,733 8,474,587
RotaTeq ($3.50 per dose)
Fully vaccinated
children
Health system
cost
Vaccine
cost
Total vaccination
program
Averted Outpatient visits
cost
Averted Hospitalizations
cost
Net Cost
2019 59,759 342,450 738,202 1,080,652 36,159 233,358 811,134
2020 56,743 325,165 700,941 1,026,106 34,828 224,765 766,513
2021 56,104 321,507 693,055 1,014,562 34,780 224,454 755,329
2022 57,124 327,350 705,650 1,032,999 34,482 222,535 775,982
2023 59,104 338,695 730,106 1,068,800 34,299 221,350 813,152
2024 60,971 349,393 753,168 1,102,560 34,176 220,558 847,827
2025 61,930 354,890 765,017 1,119,906 34,054 219,770 866,083
2026 61,681 353,465 761,947 1,115,412 33,497 216,179 865,735
2027 60,609 347,322 748,703 1,096,025 32,984 212,868 850,173
2028 59,049 338,382 729,432 1,067,814 32,425 209,260 826,128
593,073 3,398,618 7,326,219 10,724,837 341,685 2,205,096 8,178,056
ROTAVAC ($1 per dose)
Fully vaccinated
children
Health system
cost
Vaccine
cost
Total vaccination
program
Averted Outpatient visits
cost
Averted Hospitalizations
cost
Net Cost
2019 59,759 342,450 263,422 605,872 36,159 233,358 336,354
2020 56,743 325,165 250,125 575,290 34,828 224,764 315,698
2021 56,104 321,507 247,311 568,818 34,780 224,453 309,585
2022 57,124 327,350 251,806 579,155 34,482 222,535 322,138
2023 59,104 338,695 260,533 599,227 34,299 221,350 343,579
2024 60,971 349,393 268,762 618,155 34,176 220,558 363,421
2025 61,930 354,890 272,990 627,880 34,054 219,769 374,057
2026 61,681 353,465 271,895 625,360 33,497 216,179 375,684
2027 60,609 347,322 267,169 614,491 32,984 212,868 368,639
2028 59,049 338,382 260,292 598,674 32,425 209,260 356,989
593,073 3,398,618 2,614,305 6,012,923 341,684 2,205,094 3,466,145
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cost-effective intervention at most thresholds, other critical con-
siderations around affordability, feasibility, and status of other
new vaccine introductions should be part of decision-making [48].
Budget impact varies depending on which vaccine is consid-
ered. While ROTARIX and RotaTeq are relatively similar from a
cost perspective, there is an economic argument for Mongolia to
choose ROTAVAC for a potential introduction. With ROTAVAC,
the vaccination program cost would likely be the lowest and the
most affordable with a net cost approximately 70% lower than
ROTARIX and RotaTeq. To our knowledge, this is the first
analysis that demonstrates such a clear economic argument for
ROTAVAC. While product choice is a multifactorial decision and
this is a single study, this analysis suggests that countries that can-
not access Gavi-like prices for ROTARIX and RotaTeq may have
an economic incentive to consider new products.
There are several limitations to our analysis. First, the surveil-
lance in Mongolia focuses on hospitalized cases only. As a conse-
quence, there is limited local data on non-severe rotavirus
disease and we had to rely on uncertain assumptions regarding
access to care. The study, therefore, may not capture all non-
severe cases and may underestimate the costs related to non-
severe visits. Furthermore, because surveillance data were an
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RVGE deaths per 100,000 (16.5 ; 20)
Incremental health system cost per dose ($0.50 ; $2.50)
Vaccine efficacy (low ; high)
Discount rate (1% ; 5%)
RVGE severe hospitalizations (795 ; 2,825)
Inpatient admission costs* ($87.10 ; $348.40)
Vaccine price per dose ($2.02 ; $15.76)
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Fig. 4. One-way sensitivity analysis of cost per DALY averted over 10 years (societal perspective).
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important input into our incidence calculations, these data are also
uncertain. Incidence and access to care data are critical inputs and
are explored in the scenario analysis. Second, assessing the cost
linked to the immunization program was challenging, as immu-
nization program costs in Mongolia are often integrated into more
general cost categories [49]. In addition, the country was in the
process of updating its comprehensive multi-year plan at the time
of this analysis. This made the assessment of incremental health
system costs linked to rotavirus vaccination difficult so we elected
to use internationally validated estimates. This approach obliged
us to assume a similar incremental health system cost for the
delivery of several products. This is a critical consideration when
considering alternative products, and we were not able to capture
cost differentials linked to specific product characteristics such as
volume.
As Mongolia weighs the decision to introduce rotavirus vaccine
into its routine childhood immunization schedule, the results of
this analysis suggest that a rotavirus vaccination program will
avert substantial disease burden and will likely be highly cost-
effective in Mongolia.
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